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Abstract
We use a computational model to explore the effect of foam cell accumulation on plaque
regression following an increase in high density lipoprotein (HDL) influx into the plaque. Ath-
erosclerotic plaque formation is the outcome of cellular and cytokine responses to low den-
sity lipoproteins (LDL) that penetrate the artery wall following an injury to the endothelium
and become modified. We modelled the cells and cytokines that are most important in pla-
que formation using partial differential equations. The model includes monocytes and mac-
rophages, foam cells, macrophage chemoattractants, endothelium-stimulating cytokines,
modified low density lipoproteins (mod LDL) and HDL. We included interactions both at the
endothelium surface and inside the artery wall. The model predicts that when HDL influx into
a well-established plaque with large numbers of foam cells is increased, the plaque may not
regress but may continue to grow at a slower rate. If HDL influx is increased when a model
plaque is recently established and has fewer foam cells, then the plaque does regress. If
modLDL influx into the plaque is lowered at the same time that HDL influx increased or the
capacity of the HDL to remove cholesterol from foam cells is increased, then the plaque is
more likely to regress. The predictions of the model are in qualitative agreement with experi-
mental studies in mice and rabbits. The results suggest that the intrinsic dynamics of reverse
cholesterol transport by HDL are important in determining the success of HDL raising in pro-
moting plaque regression.
Introduction
There is a well-known correlation, at a population level, between high levels of high density
lipoprotein cholesterol (HDL-C, often called “good cholesterol”) in the blood plasma and a
reduced risk of cardiovascular disease in humans [1–3]. Following disappointing results from
large clinical trials of drugs that are known to raise blood HDL-C [4–7], it has become clear
that it is the number of HDL particles [8, 9] and their efficacy [9, 10] that correlate most closely
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with the risk of cardiovascular disease. Levels of HDL-C, the cholesterol carried by HDL parti-
cles, broadly correlate with the number of HDL particles [9] but raising the amount of choles-
terol carried by HDL particles does not necessarily result in an increase in the total number
of HDL particles and so may not result in increased action by HDL [11, 12]. In this paper we
explicitly focus on HDL particles which act to remove lipid from macrophages and not on
HDL cholesterol (HDL-C).
There is experimental evidence from animal models which suggests that raising HDL may
lead to plaque regression in recently established plaques when the number of HDL particles is
increased, [13–15], but not in older plaques [16–19]; it will only reduce the rate of progression
in these older plaques.
As plaques grow, they may develop lipid cores, calcification and collagen caps which early
plaques do not have. These structures still allow cholesterol to be removed from the plaque,
leading to regression in late stage plaque [16, 18] which suggests that structures typical of late
stage plaques do not prevent lipid from entering or exiting plaques. It is likely, therefore, that
the failure of increased HDL in the bloodstream to promote plaque regression in late stage pla-
que is due to something other than the plaque becoming impermeable to lipoproteins due to
changes in its structure.
Plaque formation and growth are complicated and include many interactions between cells,
lipids, cytokines and other factors [20]. Many of these interactions are nonlinear; that is, the
reaction rate is not proportional to the concentration or density of the inputs. For example,
the uptake rate of modLDL by macrophages will saturate as the concentration of modLDL
increases, because the rate that each macrophage can internalise modLDL is inherently limited
by the number of receptors in the cell membrane or even by the area of the cell membrane
itself. Therefore as modLDL availability in the artery wall increases, the rate that modLDL is
removed by macrophages will not necessarily remain proportional to modLDL availability.
The consequences of nonlinear interactions are well known in biological systems such as
ecology and neuroscience [21, 22]. The state of the system may undergo sudden dramatic
switches in response to a small change in inputs or the effect of a change in inputs may depend
on the current state of the system—for example, a change may produce an effect early in the
development of the system, but not later. Mathematical and computational modelling of such
systems shows that these effects are not random but qualitatively predictable.
We propose a computational model for plaque growth which includes the action of HDL
and predicts that plaques will not regress if HDL particle influx into the plaque is increased too
late in plaque development. In our model we consider only plaques which do not have necrotic
cores, but may contain large numbers of foam cells and macrophages. We define regression in
this model as a reduction in the number of inflammatory macrophages and foam cells. The
failure of HDL to promote plaque regression in the model is due purely to the inherent dynam-
ics of plaque growth and of HDL action. Increasing functional HDL influx too late in plaque
development only attenuates plaque growth and does not enable plaque regression.
Reducing the size of necrotic cores in advanced plaques is a major goal of clinical interven-
tion and therapy, particularly following an ischaemic event such as a heart attack or stroke.
The model presented here only addresses the reduction in foam cell numbers and therefore
decreasing the amount of intracellular lipid in the plaque, rather than the removal of the extra-
cellular lipid found in necrotic cores. Free lipid that is removed from necrotic cores by macro-
phage phagocytosis, however, will become intracellular lipid as an intermediate step in its
removal from the plaque. In this way, macrophages which contain lipid ingested from the
necrotic core may also be part of the foam cell population. This model, therefore, may give
some indirect insight into necrotic core regression by addressing the removal of ingested lipid
from foam cells by HDL.
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Previous mathematical and computational models for plaque development that include the
action of HDL have focused on the relative importance of different functions of HDL [23] or
predicting risk as a function of the balance between HDL-C and LDL-C [24]. Here we focus
specifically on the impact of the timing of changes in the rate of HDL influx into the plaque on
plaque development and regression.
Modelling and methods
The model that we present here focuses on immunological processes within the artery wall.
Many of the immunological processes included in the model are inherently in vivo processes
and difficult to measure directly. This model, therefore, gives qualitative insight only because
of the difficulty in obtaining data to fit the parameters required for a fully quantitative model.
Nevertheless qualitative models provide valuable insights, generate hypotheses and motivate
the data collection that is needed to produce fully quantitative models.
We emphasise that this model is not concerned with fluid flow within the blood vessel [25]
nor with the details of the relationship of LDL and macrophage perfusion to endothelial dys-
function [26]. Both of these aspects are well-studied with models and experimentally. Instead,
we assume that the endothelium (the layer of cells that line the inside of the blood vessel) is suf-
ficiently damaged to permit plaque formation and we model only the immunological processes
inside the artery wall.
Fig 1 shows schematically how the model works. We assume that the injured endothelial
cells allow LDL into the intima, the layer of the artery wall nearest to the bloodstream. This
LDL rapidly becomes modLDL and stimulates an immune reaction in the endothelial cells on
the boundary. In response to modLDL, endothelial cells produce monocyte chemoattractants
such as MCP-1, which draw monocytes into the intima. Endothelium-stimulating (ES) cyto-
kines such as TNF-α, produced in the intima, stimulate the endothelial cells to produce adhe-
sion molecules which act on monocytes in the blood stream and further increase the rate of
monocyte recruitment. Inside the intima the monocytes rapidly differentiate into macro-
phages which move towards modLDL, and consume it. Stimulated by modLDL consumption,
macrophages produce more monocyte chemoattractant and also ES cytokines. As macro-
phages consume modLDL, they become foam cells. The model applies to plaque development
before the formation of the lipid core or collagen cap.
HDL modulates these processes in the model by inhibiting the oxidation of LDL so that
there is less modLDL entering the intima; by decreasing the number of adhesion molecules on
the damaged endothelium, which in turn reduces the recruitment rate of monocytes; and by
facilitating reverse cholesterol transport (RCT) from foam cells which then revert to macro-
phages. Macrophages have the capacity to change phenotype during plaque progression and
regression [27, 28]. There is provision in the model fora proportion of the macrophages to
revert to the original inflammatory phenotype (M1) following RCT. When macrophages revert
to the anti-inflammatory (M2) phenotype, they no longer play any part in the model as we
assume that they no longer produce pro-inflammatory cytokines such as MCP-1 and ES cyto-
kines. HDL can also promote foam cell and macrophage emigration from the plaque [29]. This
emigration from the plaque can be modelled in the same way as loss of macrophages from the
model through change of phenotype. We assume that some proportion leave the plaque after
lipid has been removed by HDL and those macrophages whose fate is emigration are no longer
part of the model.
The model consists of six partial differential equations with associated boundary condi-
tions. We solved the equations in one spatial dimension which is taken as a radial line from the
endothelium to the boundary between the intima and the media which is the next outward
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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Fig 1. Schematic diagram of the model. Diagram of processes in the endothelium and intima in early
plaque formation with a flow-chart representation of the model interactions on the endothelium (top) and in the
intima (bottom) between modLDL, monocytes/macrophages, chemoattactants, ES cytokines, foam cells and
HDL. A plaque is initiated when the endothelium is injured and allows LDL to enter and causes it to become
modified so that the LDL particles become oxidised or modified in other ways. These modLDL particles
provoke an immune reaction that causes monocytes to enter the blood vessel wall from the blood stream and
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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layer of the artery wall. This assumes that the model domain is far enough away from the edges
of the plaque that there is negligible net movement of cells and cytokines either circumferen-
tially or axially in the plaque. The endothelial boundary, between the artery wall and the blood-
stream is set at x = 0. The spatial dimension is scaled by the width of the intima, so that the
medial boundary is at x = 1. To keep the computations tractable, we assumed that this domain
is fixed in length and so the plaque does not significantly distort the intima. This is a reason-
able approximation for early plaque but may not be a good approximation for later plaques.
The six dependent variables are ℓ, h, p and q, the concentrations of modLDL, HDL particles
with capacity for RCT, monocyte chemoattractant and ES cytokine respectively and m and N,
respectively the density of macrophages/monocytes and foam cells in the tissue. We assume
that the timescale of LDL modification is much faster than the timescales of other events in the
model [30] so that we only model the LDL which will become modified on entry to the intima
and we ignore the LDL that enters the intima but remains unmodified. We also model macro-
phages and the monocytes that will differentiate into macrophages that ingest modLDL as a
single class of cells in the model.
The model has a large number of parameters. The definition and symbol for each of
these parameter are given in Table 1 together with the numerical value used in numerical
computation.
We assume that each macrophage consumes modLDL at a rate that is proportional to the
concentration of modLDL when modLDL concentration is low. When modLDL concentra-
tion is high, the rate of consumption tends to a fixed upper limit [31]. In the model, these
saturating kinetics for modLDL consumption by a single cell are represented by the function
ℓ/(1 + ℓ) where ℓ has been scaled so that the constant in the denominator is 1. This uptake rate,
which is essentially Michaelis-Menten kinetics, is the simplest possible saturating function.
The first term on the right hand side in each of Eqs (1) to (6) models the diffusion or ran-
dom motion of the lipid particles, cytokines or cells in the tissue. We acknowledge that many
of these species may undergo binding to other substrates within the tissue which constrains
their ongoing movement. However Fickian diffusion is a reasonable representation of move-
ment before binding takes place [32] and has the added mathematical benefit of fostering sta-
ble numerical solutions to the model equations.
The last term on the right hand sideof each of Eqs (1) to (5) models linear loss due to chemi-
cal decay, cell apoptosis or other processes not explicitly included in the model.
In Eq (1) for the rate of change of modLDL, concentration ℓ, the second term on the right











  d‘‘ : ð1Þ
The second term on the right hand side of Eq (2) for the change in concentration of HDL,
h, models loss of those HDL particles which have the capacity to take up lipid as HDL particles
receive lipids via RCT from foam cells. This term saturates as h increases, since each foam cell
has a finite number of transporters in its membrane and so there is a limit to the rate that each
cell can engage with HDL particles. The equation for the rate of change of the concentration of
differentiate into macrophages which consume modLDL. The macrophages become filled with cholesterol
and take on a foamy appearance under the microscope. If the cholesterol is not removed from the cells, these
foam cells accumulate in the intima. HDL particles transport cholesterol out of foam cells and cause the
plaque either to regress or grow more slowly. HDL also acts to reduce the modification of LDL and the
excitation of the endothelium which reduces the rate that monocytes enter the plaque.
https://doi.org/10.1371/journal.pone.0187674.g001
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For chemoattractant, concentration p, and ES cytokine, concentration q, the second term
on the right hand sides of Eqs (3) and (4) models production of these cytokines by macro-
phages in response to macrophage consumption of modLDL [33, 34]. This rate of production
Table 1. Parameter values used in the model. It is difficult to obtain experimentally valid parameter values for all the parameters in the model and conse-
quently these values are not available in the literature. In particular it is extremely hard to measure in vivo values, but most of the parameter that the model
requires have not even been measured in vitro. Therefore, most values are order of magnitude estimates. Since the aim of this study is to produce qualitative
results, having exact, experimentally determined parameter values is less critical than for a quantitative predictive model. The values below have been
rescaled in space and time in order to normalise the intima width. We take an intima width of 40 μm [59]. We use a time scale of * 7.7 × 106 s (approximately
89 days) to rescale the equations. Further details on the rescaling can be found in [58].
Parameter Value after rescaling Reasoning/Description
Dℓ 104 Diffusion of LDL paricles * 2 μm2/s. [60]
μℓ 105 Estimated consumption rate of LDL by macrophages.
dℓ 101 Estimated decay rate of LDL.
σℓ 103 Estimated influx rate of LDL.
Dp 106 Diffusion of chemoattractant * 200 μm2/s. [61]
μp 106 Estimated production rate of chemoattractants by macrophages consuming LDL.
dp 103 Decay rate of chemoattractant * 10−4/s. [62]
σp1 10
5 Estimated production rate of chemoattractants by endothelial cells by LDL stimulation.
σp2 10
4 Estimated production rate of chemoattractants by endothelial cells by ES cytokine stimulation.
βp 100 Estimated saturation constant of LDL stimulation of endothelial cells in the production of chemoattractant.
Dm 102  Dℓ. Estimated random movement of macrophages.
χm 103 Estimated chemotactic term due to scavenging of LDL.
μm 102  μℓ. Estimated coversion rate of macrophages to foam cells via LDL consumption.
dm 100 Estimated decay rate of macrophages.
σm 10−3 Estimated adhesion efficacy on inward migration of monocytes into the intima.
A 10−2 Estimated efficacy of ES cytokines on the transmigration of monocytes into the intima.
P0 10−1 Estimated background chemoattractant levels.
Dq 106 Diffusion of chemoattractant * 200 μm2/s. [61]
μq 106 Estimated production rate of ES cytokines by macrophages consuming LDL.
dq 103 Decay rate of chemoattractant * 10−4/s. [62]
σq 100 Estimated outflux of ES cytokines
DN 10−2  Dm. Estimated random movement of macrophages.
νN 101 Estimated coversion rate of foam cells to macrophages via HDL reverse cholesterol transport.
Dh 104 Assumed same as Dℓ.
νh 104 Estimated consumption rate of HDL through reverse cholesterol transport.
dh 101 Estimated decay rate of HDL.
κ 100 Estimated saturated constant of HDL in reverse cholesterol transport.
σh Varies Estimated influx of HDL into the intima.
αℓ 101 With γℓ, estimated efficacy of HDL on the oxidation of LDL.
γℓ 10−1  αℓ.
αm 101 With γℓ, estimated efficacy of HDL on the oxidation of LDL.
γm 10−1  αm.
https://doi.org/10.1371/journal.pone.0187674.t001
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 6 / 23




















  dqq : ð4Þ
Macrophages, density m, move towards modLDL (second term in Eq (5)) [33] and convert
to foam cells as they consume modLDL (third term). Only a proportion θ of foam cells revert
to macrophages with an inflammatory phenotype after RCT (fourth term). Some macrophages
take on a non-inflammatory phenotype after exposure to HDL [35] and we do not include this
macrophage phenotype in the model. Other macrophages leave the plaque after RCT [29] and
are also not included in the model once their fate is determined so only a proportion θ of foam
cells that undergo RCT return to the pool of inflammatory macrophages. Hence the equation




















  dmm : ð5Þ
Foam cells, density N, are generated as macrophages consume modLDL (second term,














At the endothelial boundary, x = 0, the boundary conditions model the activity of the endo-
thelium. HDL flows into the plaque, ES cytokines flow outwards at a rate proportional to the
concentration of ES cytokines in the intima, foam cells do not cross this boundary:
Jh ¼ sh ; ð7Þ
Jq ¼   sqq ; ð8Þ
JN ¼ 0 : ð9Þ
where Jh, Jq and JN are the inward flux of HDL, ES cytokines and foam cells respectively across
the boundary. The flux of modLDL across x = 0 into the intima, Jℓ, is modulated by the pres-





The flux of monocyte chemoattractant Jp into the intima is determined by the rate that it is
produced by endothelial cells. This production is a function of ES cytokine concentration [37]




þ sp2q : ð11Þ
The inward flux of macrophages is dependent on endothelial excitation by ES cytokines, by
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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ð1þ AqÞðp   P0ÞHðp   P0Þ; ð12Þ
where H(x) is the Heaviside function and P0 is the concentration of monocyte chemoattractant
in the lumen of the artery.
All variables have no flux boundary conditions on x = 1; that is, we assume that there is no
significant loss of cells or cytokines through the media. This does not prevent lipid-laden HDL
passing out through the outer wall of the blood vessel as once an HDL particle loses the ability
to accept lipid it is no longer included in the model—this is expressed in the loss term which is
the last term on the right hand side of Eq (2)—and so the no flux assumption does not apply to
lipid-laden HDL. In the same way, macrophages that emigrate from the plaque or change to a
non-inflammatory phenotype cease to be part of the model and so do not require a boundary
flux term in the model. We are able to model macrophage emigration in this way since we do
not track the volume of cell or lipids in this model.
The set of partial differential equations (PDEs) Eqs (1–6) with boundary conditions (7–12)
were solved for time-dependent solutions using the software package FlexPDE which uses
finite element methods to solve systems of PDEs. The bifurcation curves for the steady states
of the set of equations were found numerically using the numerical continuation package
AUTO [39]. At the steady state, this system of PDEs reduces to an equivalent system of
ordinary differential equations (ODEs) in the independent spatial variable x. We first used
FlexPDE to find the values for each dependent variable across the discretised spatial domain,
for a value of σh that guarantees a steady state for the foam cell population. Using these values
as a starting point we applied AUTO to the ODE system, to find the bifurcation curve as a
function of σh. The complete set of parameter values used in these computations are given in
Table 1.
It is possible to formulate models for plaque development which have a moving boundary
that enables the increasing numbers of foam cells to distort the intima [40]. Here we are pri-
marily concerned with HDL dynamics rather than intimal thickening and we have made the
simplifying assumption that the domain is fixed; that is, that the influx of modLDL and macro-
phages do not significantly distort the intima.
Results
The solutions of the model produce spatial profiles across the intima of modLDL concentra-
tion, and macrophage and foam cell density. These profiles change over time as the plaque
develops. The model plaques start with no modLDL, cytokines, inflammatory macrophages or
foam cells present in the intima. At first, each profile has a maximum at, or close to, the endo-
thelium. As the plaque develops, both cells and cytokines become evenly spatially distributed
across the intima. The density of macrophages in the intima in these model plaques always set-
tles to a fixed equilibrium, which does not change after an initial period of growth, but the den-
sity of foam cells may either continue to grow or settle to a fixed equilibrium where the plaque
is neither growing nor shrinking (Fig 2).
Fig 3(a) shows a bifurcation diagram, computed from the model. This diagram gives quali-
tative information about foam cell accumulation at different rates of HDL influx. The vertical
black arrows represent model plaques (labeled A to E) that are developing over time each with
a fixed rate of HDL influx. The direction of the arrows indicates whether the plaque is growing
or shrinking. The horizontal dashed lines represent instantaneous changes in HDL influx.
The solid curve represents the fixed equilibrium and is known mathematically, as an attractor.
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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Plaques grow or shrink so as to get closer to the attractor. The dashed curve is known as the
repellor. Plaques grow or shrink so that they move away from this curve. The dashed and solid
curves meet at a point known as a bifurcation point or tipping point. We have labeled the rate
of HDL influx at the bifurcation point Sh. When the HDL influx rate is below Sh, the density
of foam cells in the model plaque will always increase as no equilibrium state exists. Fig 3(b)
shows the accumulation of foam cells with time in each of the model plaques represented in
Fig 3(a).
Plaque A represents a plaque with low HDL influx. Over time, the density of foam cells in
Plaque A continues to grow, as shown in Fig 3(b). Plaque B on the other hand represents a pla-
que with a high rate of HDL influx. The density of foam cells in this plaque grows with time,
but approaches the fixed equilibrium represented by the solid curve in Fig 3(a).
The effect of changing the rate of HDL influx in the model depends on the timing and mag-
nitude of the change. Plaque C grows as the same rate as Plaque A initially, but after Plaque
C has grown for a short time, the rate of influx of HDL into the plaque is instantaneously
increased to the same HDL influx rate as Plaque B. When this happens, Plaque C loses foam
cells via RCT and regresses to the fixed equilibrium foam cell density. Plaques D and E also
grow in the same way as Plaques A and C initially, but the rate of HDL influx is increased later
Fig 2. Macrophage and foam cell density over time. (a) Macrophage density in the intima and (b) foam cell density when the plaque
grows unboundedly. Plots (c) and (d) show macrophage and foam cell density respectively where foam cell numbers settle to a fixed
equilibrium. Note: all variables are scaled with respect to intima width and indicative time scale.
https://doi.org/10.1371/journal.pone.0187674.g002
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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than for Plaque C. For Plaque D, the HDL influx rate is increased to the same value as Plaque C
but the plaque continues to grow, albeit at a slower rate than for Plaque A. The difference
between plaques D and C is the timing of the increase in HDL influx; in Plaque C the plaque
was smaller when HDL influx increased and the new influx rate moves the plaque to between
the dashed and solid curves in Fig 3(a). The plaque develops so that is gets closer to the fixed
equilibrium, represented by the solid curve and further from the repellor which is represented
by the dashed curve. Plaque D has grown sufficiently that, when HDL influx is increased,
the plaque is above the dashed curve and so foam cells continue to accumulate as the plaque
moves away from the repellor. If the rate of influx of HDL is increased at the same time as in
Plaque D but by a larger amount, then the plaque will fall in the region between the solid and
dashed curves and will regress (Plaque E).
In general, when the rate of HDL influx into the plaque is less than Sh (the HDL influx rate
at the bifurcation point), there is no equilibrium and so the density of foam cells in the plaque
continues to grow. If the rate of HDL influx is greater than Sh then there is an equilibrium or
attractor where the density of foam cells in the plaque does not change. If the HDL influx
remains constant and high enough, then a newly initiated plaque will approach this equilib-
rium and remain small. If HDL influx later drops below Sh the plaque will start to grow again.
A subsequent increase in HDL influx may or may not lead to plaque regression and a conse-
quent return to the small plaque with a fixed density of foam cells; this will depend on the tim-
ing and magnitude of the change in HDL influx.
The placement of the bifurcation point depends on various physiological parameters in the
model (Fig 4). As the cholesterol efflux capacity of HDL particles increases, the bifurcation
point moves left and so plaques can settle to a fixed equilibrium at lower rates of HDL influx.
As the rate of LDL influx and consequent generation of modLDL increases, the bifurcation
point moves right, so that the HDL influx rate that is required for a plaque to be at equilibrium
increases. As the proportion of foam cells that revert to M2 type macrophages after reverse
cholesterol transport increases, the repellor curve becomes steeper and so an increase in
HDL influx is more likely to promote regression. Other parameters that affect the shape and
Fig 3. Model predictions from bifurcation diagram. (a) Bifurcation diagram showing the density of foam cells at equilibrium as
a function of the rate of influx of HDL. The solid blue curve represents the attracting equilibrium and the dashed red curve the
repellor. The black arrows and lines represent various plaques labeled A–E whose size changes with time; the dashed horizontal
lines represent rapid changes in HDL influx rate; the vertical arrows represent changes with time due to intrinsic dynamics in the
model tissue. (b) Plaques A–E plotted as a function of scaled time. As shown in the bifurcation diagram plaques B, C and E tend to
the fixed equilibrium which has low foam cell density, but the density of foam cells in plaques A and D continue to grow. The scales
on the axes are a qualitative indication only as there is limited information about the exact values of the input parameters in the
model.
https://doi.org/10.1371/journal.pone.0187674.g003
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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Fig 4. Equilibrium foam cell density for changing physiological parameters. Foam cell density at
equilibrium (the attractor) and the repellor are plotted against HDL influx showing the effect of (a) increasing
the cholesterol efflux capacity (CEC) of HDL particles; (b) increasing the influx of modLDL into the plaque and
(c) increasing the proportion of macrophages that revert to M2 type after RCT. The attracting equilibria are
indicated by the solid curves; the repellors by dashed curves. In (a), as cholesterol efflux capacity increases,
the bifurcation point moves left so that the equilibrium exists for lower rates of HDL influx. In (b), as modLDL
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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placement of the curve in the bifurcation diagram, include the response of the endothelium to
modLDL and the number of monocytes available in the blood stream (Fig 5).
Reverse cholesterol transport by HDL in the model is key to determining whether plaques
continually grow or settle to an equilibrium where foam cells do not accumulate. Removing
RCT from the model removes the attracting equilibrium so that plaques with fixed foam cell
density cannot form and the only possibility is that plaques continue to grow. The effect of
reducing CEC is shown in Fig 4(a). As CEC decreases, the bifurcation point moves right.
When the HDL has no capacity to remove cholesterol from foam cells—that is, there is no
influx increases, the bifurcation point moves right so equilibrium only exists for higher rates of HDL influx. In
(c), as the proportion of foam cells revert to M2 rather than M1 macrophages increases, the slope of the
repellor curve increases so that it is more likely that a plaque will fall below the repellor curve if HDL influx is
increased and consequently will regress. The blue curve in each plot is the same curve as in Fig 3(a).
https://doi.org/10.1371/journal.pone.0187674.g004
Fig 5. The effect of different HDL actions on equilibrium foam cell density. Plots showing where equilibrium plaques with a fixed
density of foam cells exist as a function of σh the rate of influx of HDL and (a) σm which governs the rate of influx of monocytes and may be
thought of as the availability of monocytes in the blood stream; (b) g‘
a‘
which governs the rate that LDL is modified and hence the rate that
modLDL enters the model plaque; and (c) gm
am
which governs the excitability of the endothelium in response to modLDL and its propensity to
express adhesion molecules and thereby recruit macrophages to enter the lesion. In each plot, the curve is the locus of the bifurcation point.
https://doi.org/10.1371/journal.pone.0187674.g005
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
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RCT—then the bifurcation point and the fixed equilibrium disappear entirely. Similar infor-
mation is presented in a different way in Fig 6. The anti-inflammatory effect of HDL on the
endothelium and its anti-oxidative action alone is insufficient for plaque regression or, indeed,
even for equilibrium in this model.
Discussion
The results of this model suggest that the history of a plaque’s growth is as important as the
rate of influx of HDL particles that the plaque experiences. If a plaque is well-established
with a substantial foam cell density, then the model predicts that raising HDL availability by a
moderate amount may not lead to regression but only to a slower rate of growth. Conversely,
raising HDL influx very early in plaque growth or by a large amount will lead to regression.
The model results are consistent with experimental studies on rabbits and on ApoE-/- and
Ldlr-/- mice. A study on rabbits that were fed an atherogenic diet for eight weeks and then
injected weekly with HDL particles showed that the extent of fatty streaks in the aorta was
about 50% lower than in the treatment group compared to both the baseline and the control
groups after 30 days [13]. Another study using Ldlr-/- mice injected with a human ApoA-I
adenovirus after five weeks on an atherogenic diet before sacrifice four weeks later, showed a
reduction in aortic lesion size of 70% compared to baseline groups and an even greater reduc-
tion compared to control groups [14]. A similar study on Ldlr-/- mice with a short initiation
phase did not produce regression but did demonstrate a greatly reduced progression rate so
that 24 weeks after ApoA-I adenovirus injection the treatment group had lesions that were
50% smaller than the control group [15].
Fig 6. The existence of equilibrium plaque as a function of cholesterol efflux capacity and HDL influx.
This plot shows where equilibrium plaques with fixed density of foam cells exist as a function of σh the rate of
influx of HDL and νN which specifies the cholesterol efflux capacity of HDL and governs the rate of reverse
cholesterol transport from foam cells. The solid curve is the locus of the bifurcation point; that is, of Σh as νN
changes. This curve separates the region where an equilibrium plaque exists from the region where there is
no equilibrium. As the cholesterol efflux capacity of the HDL particles decreases, the bifurcation point occurs
at increasingly greater values of σh than when cholesterol efflux capacity is high. If cholesterol transport rates
are very low then very high rates of HDL influx are required for a plaque to exist in equilibrium. On the locus of
the bifurcation point, as νN! 0 then σh!1 which suggests that there it is impossible to have an equilibrium
plaque when there is no reverse cholesterol transport.
https://doi.org/10.1371/journal.pone.0187674.g006
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Studies with Ldlr-/- or ApoE-/- mice where HDL levels were increased after a period of pla-
que initiation of 6 months or longer followed either by human ApoA-I gene transfer [16, 17]
or by transplant of the aorta into a wild-type mouse [18], did not produce regression in lesion
areas even after several months of increased HDL levels but did show that plaques in the treat-
ment group did not progress as rapidly as plaques in control animals. In another study [19]
ApoE-/- mice were given ApoA-I via infusion or gene transfer after either 8 or 34 weeks on ath-
erogenic diets. Plaques in mice that were given infusions or gene transfer after 8 weeks grew
more slowly than in untreated mice. There was no difference in plaque size between untreated
mice and mice that were treated at 34.
The results of our model are consistent with the results of these studies which, together,
suggest that an increase in HDL availability early in the life of a plaque is more likely to pro-
duce regression than a later increase in HDL influx.
Reducing the influx of modLDL into the plaque moves the bifurcation point to the left so
that the equilibrium with low foam cell density will exist for lower rates of influx of HDL (Fig
4(b)). This allows us to compare the predictions of the model to the results of a study by Feig
et al. [29]. In this study ApoE-/- mice were fed an atherogenic diet for 16 weeks and their aortas
were each transplanted into genetically different mice so that the transplanted aortas were
either in a similar environment to the donor mouse (the control) or in an environment with
raised HDL-C compared to the donor mouse, lowered LDL-C or both. (We assume here that
these correlate well with HDL and LDL particle number [9].) The recipient animals were on a
chow diet and sacrificed after one week. Table 2, together with Fig 7, summarizes the results
of this study and their interpretation according to this model. In each case, the experimental
results can be explained qualitatively using the model and these explanations are consistent
with one another.
In contrast to much of the research with animal models, clinical studies on HDL-raising in
humans are usually conducted in patients with late stage plaque, usually following the onset of
clinical symptoms such as an acute coronary event of other evidence of vascular disease. The
modelling suggests that the large reduction seen in plaques in animal models are unlikely to
be observed in these late-stage plaque studies. The complicated structures of late-stage plaque
may also be a confounding factor. Generally speaking reductions in volumes in advanced
human plaques are small compared to the reductions in the volume of early plaques seen in
animal studies. Typically patients’ HDL particle numbers are raised by weekly infusions for up
to two months of an ApoA-I mimetic [41], an ApoA-I/phospolipid complex [42] or of their













ApoE−/− No change: HDL-C
remains low; LDL-C
remains high
Increasing trend Fig 7(a) No change in plaque behaviour. Plaque continues to grow.





Fig 7(b) Change in HDL levels puts plaque to the right of the
bifurcation point and below repellor so the model plaque
regresses.
ApoA-I−/− HDL-C remains low;
LDL-C falls to low levels
Decreasing trend Fig 7(c) Decrease in LDL moves the curve left; the plaque can now
regress to the equilibrium.
Wild Type HDL-C rises to normal
levels




Fig 7(d) Decrease in LDL moves curve left. Increase in HDL moves
the plaque right. Plaque tends to an equilibrium that is smaller
than for the ApoAI−/− recipient
https://doi.org/10.1371/journal.pone.0187674.t002
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 14 / 23
own delipidated HDL [43] and the plaque volume in a target coronary artery was measured
at the end of the treatment. These treatments, at best produce a reduction of less than 7% in
plaque volume relative to baseline. The only exception to this is the study by Shaw et al [44]
which showed a reduction of 62% in macrophage lipid content and 58% in macrophage size
relative to the placebo group in plaques that were excised from the femoral artery a week after
infusion with reconstituted HDL.
The existence of the bifurcation point at the critical value of HDL influx Sh suggests why
low HDL-C in humans (which is assumed to correlate with HDL particle number or action
[9]) is consistently correlated with increased risk of CVD, but high HDL-C is not necessarily
correlated with low CVD risk [12]. If this switch between continual plaque growth with no
equilibrium plaque size and an accessible equilibrium exists in vivo, then further increases in
HDL particle numbers which usually correlates with increases in HDL-C [9], provide very little
benefit once HDL influx is sufficiently high for there to be enough HDL for a plaque to settle
at equilibrium.
The model also highlights the key role of the cholesterol efflux capacity (CEC) of HDL. If
CEC is high then plaques will reach an equilibrium for lower values of HDL influx than if CEC
is low (Fig 6). When CEC is low, a plaque is more likely to continue to grow. This result agrees
with population-level data on the relation between CEC and heart attack and stroke [45].
There are only a few previous modelling studies which include HDL [23, 46]. There is evi-
dence in these studies that bifurcations, similar to those found here, exist in their models and
Fig 7. Diagrammatic representation of model predictions described in Table 1. Sketch of changes
predicted by the model in plaque size after transplant into recipient mice: (a) ApoE-/-; (b) hAI/ApoE-/-; (c)
ApoA-I-/-; (d) Wild Type. The curves in each plot represent the attractors and repellors. The solid curves
represent the attractors or fixed equilibrium solutions and the dashed curves represent the repellors. Where
there are two sets of curves, the heavier set of curves corresponds to the plaque after transplant and the
lighter curve corresponds to the plaque before transplant. The solid arrow represents plaque growth before
transplant and the dashed arrow represents post-transplant changes.
https://doi.org/10.1371/journal.pone.0187674.g007
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can determine the fate of a plaque when HDL input or efficacy is changed. Cohen et al. [23]
present bifurcation diagrams which show that bifurcation points exist and that these can lead
to sudden switches between plaques being at equilibrium and growing unboundedly. In
Cohen et al.’s model, high rates of macrophage influx lead to continual growth but low rates of
macrophage influx lead to plaques settling to one of two possible equilibriums. However, these
bifurcation diagrams depend on the rate of macrophage influx rather than the rate of HDL
influx. Because in Cohen et al.’s model macrophage influx is implicitly dependent on HDL
concentration, this gives a limited insight into the anti-inflammatory effect of HDL on the
endothelium in promoting plaque equilibrium. Cohen et al. [23] further show that the effects
of changing the rate of macrophage influx depends on when the change is made. If the rate of
macrophage influx is reduced early in the plaque’s life, a rapidly growing plaque will settle to
equilibrium, but if the rate of macrophage influx is reduced later in the plaque’s life in their
model, then the plaque continues to grow, but at a slower rate.
Friedman and Hao [46] show that small increases in HDL efficacy in their model lead to
a reduction in the rate of plaque growth although plaques do continue to grow, but large
increases in HDL efficacy lead to a reduction in plaque weight and macrophage density. It is
not clear whether these regressing plaques reach an equilibrium in their model.
Both these models and the model that we present in this paper suggest that nonlinearities in
the dynamics of HDL action in plaques may lead to sudden changes in plaque behaviour after
periods of consistent growth or equilibrium when the plaque environment changes due, for
example, to the change in HDL efficacy with age [47] or decrease in LDL influx due to success-
ful treatment with statins.
There is currently ongoing interest in the infusion of HDL particles or HDL mimetics to
promote plaque regression [8, 48, 49]. This study suggests that some patterns of dosage will be
more successful than others. It also suggests that it may be possible to engineer a change in the
fate of a plaque from continual growth to regression to a small plaque in equilibrium.
Fig 8 shows the potential effect of treatment on a model plaque. For most treatments to be
effective, the model suggests that the increase in HDL levels must be maintained; that is, treat-
ment will usually need to be ongoing, in the same way that statin treatment to reduce levels of
LDL cholesterol in the blood is long term. For regression to occur in the model, the increase in
sustained HDL influx rates into the plaque must be sufficiently large that the solution for the
model plaque lies between the repelling and attracting solutions in the bifurcation diagram.
If the increase in influx of HDL is sufficiently large to drive the plaque below the threshold
imposed by the repelling solution, then the plaque will regress (Fig 8(b) and 8(c)). This is simi-
lar to model plaques C and E in Fig 3.
If the HDL influx increase is not large enough, then the only change that might be observed
is a decrease in growth rate. This is similar to model plaque D in Fig 3. A failure to create sus-
tained levels of HDL activity in plaques may be behind null results obtained in studies on
humans where HDL was infused weekly [41]. Other studies suggest that apo-AI (the protein in
HDL) decreases exponentially from the time of infusion with a half-life of at most 36 hours
[50] so that HDL concentration in the bloodstream returns to baseline levels after about 3 days
and so a weekly infusion which may result in significant variations in HDL availability may
constantly switch the plaque between decreasing to an attracting equilibrium and increasing
without bound over the weekly treatment cycle.
The model does, however, suggest that it is possible that increasing HDL influx into the pla-
que by increasing HDL via infusion for a limited time, may sometimes lead to permanent pla-
que regression. Consider a model plaque that is experiencing growth at a level of HDL influx
where there is an equilibrium solution (Fig 8(e) and 8(f)). This is illustrated in Fig 8(d). This
plaque may, for example, have started growing when the modLDL influx rate was higher and
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so the bifurcation curve has moved to the left since the plaque was initiated. This might model
the commencement of statin treatment or the effect of lifestyle changes, for example. If the pla-
que is given a sufficiently high sustained HDL influx through HDL infusion, the model plaque
will move to the region between the repellor and the equilibrium solution and regress towards
the equilibrium solution. If HDL infusion ceases and the HDL influx returns to its original
state, then the plaque will remain at equilibrium and remain small. This effect requires an
ongoing low modLDL influx into the plaque and a temporary increase in HDL that is suffi-
ciently high and lasts long enough to “reset” the plaque to the regressed equilibrium state.
Fig 8. Diagram illustrating of the effect of treatment by raising HDL influx into plaques, showing schematically the effect of a period
of infusion of HDL that leads to increased HDL influx into the plaque, both with and without a simultaneous lessening of LDL influx.
(a) HDL influx into the plaque as a function of time where there is a period of regular infusions, preceded and followed by a period of no
infusions. (b) Sketch of the bifurcation diagram showing the solution for the plaque under the HDL influx regime illustrated in (a) when LDL
influx doesn’t change. The solution evolves over time along the black curve in the direction of the arrows. When the infusions are completed the
plaque returns to a state where it cannot reach the attractor but continues to grow; (c) Sketch of plaque size as indicated by foam cell density as
a function of time under the HDL influx regime illustrated in (a) when LDL influx doesn’t change. This plot corresponds to the progress of the
plaque shown in (b) but here foam cell density is plotted explicitly as a function of time; (d) sketch of the changes in the bifurcation diagram
when LDL influx is decreased before HDL infusion begins. (This might model the introduction of statin therapy for example.) The black arrow
represents plaque growth before LDL influx decreases. We assume that the LDL influx rate is changed after the plaque has developed
sufficiently so that the solution lies above the repellor on the new bifurcation curve. (e) Sketch of the bifurcation diagram showing the solution
for the plaque under the HDL influx regime illustrated in (a) when the LDL influx is changed before HDL infusion is started. The grey arrow
represents plaque growth prior to LDL increase and HDL infusion. Since the untreated level of HDL influx now lies to the right of the bifurcation
point, the plaque will settle to an equilibrium once infusions stop since HDL infusion has reduced the size of the plaque so that the solution can
approach the attractor and reduced LDL levels ensures that the attractor is now accessible when there is no HDL infusion. This new equilibrium
is stable as long as LDL influx into the plaque remains low.; (f) Sketch of plaque size as indicated by foam cell density as a function of time
under under reduced LDL influx and the HDL influx regime illustrated in (a). This plot corresponds to the progress of the plaque shown in (e) but
here foam cell density is plotted explicitly as a function of time.
https://doi.org/10.1371/journal.pone.0187674.g008
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Large clinical trails have commenced for infusion of HDL mimetics have the application of
gene therapy as treatment for late stage plaques [48, 49, 51]. Preliminary results suggest that
regular, ongoing infusions of a HDL mimetic can reduce the area of a plaque by about 6.7% on
average [52]. However, most of these trials are being conducted on patients with advanced pla-
ques which have necrotic cores. Our model predicts that a sufficiently large increase in the
action of HDL in plaques, whether due to increasing the concentration of HDL particles or
increasing their efficacy will reduce the lipid burden of plaque macrophages and foam cells.
However, to reduce the size of advanced plaques, extracellular lipid needs first to be ingested
by cells before it can undergo reverse cholesterol transport by HDL. This ingestion of extracel-
lular lipid may be a comparatively slow process [53] and so, although the nonlinear dynamics
of HDL action that we explore in this study may be a factor in the low degree of regression of
advanced plaques, the presence of the necrotic core, which is not included in this model, may
be another fundamental cause of low rates of regression in advanced plaques which contain
extracellular lipid.
The computational model in this study has many nonlinear terms that model different fac-
ets of cell and cytokine action in plaque growth and further work is required to determine
which of these dominate in plaque formation and regression. Accurate values for most of the
parameters in the model cannot yet be obtained from the experimental literature and conse-
quently many of these are estimates or values that are obtained from other contexts or from
general considerations of how cells and cytokines behave. Nevertheless, this analysis strongly
suggests that the effects of nonlinear interactions may be significant in the dynamics of plaque
formation and regression. Several laboratory research groups [54–56] have recently begun to
characterize macrophage movement and plaque growth in terms of dynamics. It is important
to understand, in such a complicated and multifactorial process, that nonlinear interactions
occur and may lead to discontinuous switches and changes due to bifurcations. These bifurca-
tions will not occur only for changing levels of HDL influx but may also occur for other physi-
ological variables, such as the availability of monocytes in the blood stream or the influx of
LDL particles into the plaque [57, 58].
As yet, there is only indirect evidence that these types of nonlinear switches occur in pla-
ques in vivo, but if they do, there is likely to be implications for the management of plaque
growth and for strategies to promote plaque regression. This study, for example, suggests, if
the modelling is valid, that the influx rate of HDL into the arterial wall must either be increased
sufficiently early in the life of the plaque or be sufficiently substantial for the plaque to regress,
that is, for the attracting equilibrium to be accessible under the newly increased rate of HDL
influx. This raises questions about the dynamics of HDL action and RCT in plaques in addi-
tion to the plethora of questions that already surround drug interventions to increase HDL lev-
els in patients at high risk of CVD.
In conclusion this study suggests, via a computational model that there may be a bifurcation
point in plaque growth. (The bifurcation point is also called the tipping point in other scientific
contexts.) Plaques with HDL influx below this point will continue to grow but plaques with
HDL influx above this point may settle to an equilibrium where they do not grow. The model
also suggests that both the timing and magnitude of any increase in HDL influx into plaque
will determine whether or not a plaque regresses or continues to grow. Whether or not a pla-
que remains small or regresses to equilibrium depends also on the influx of LDL into the
plaque and the cholesterol efflux capacity of the functional HDL. These results suggest that
therapy that raises HDL may be most effective in preventing the growth of small plaques rather
than promoting the regression of large plaques.
A theory of the dynamics of early plaque growth and regression has the capacity, not only
to generate new hypotheses, but also to provide explanations of anomalous observations and a
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framework to synthesize research results. Developing this theory and devising biologically
valid computational and mathematical models to encapsulate theoretical ideas will require
care and persistence and is unlikely to be simple or straightforward. This analysis is one early
step in the journey.
Acknowledgments
We thank Erin Walsh for help with drawing Fig 8 and Fred Curtis for assistance with format-
ting figures.
Author Contributions
Conceptualization: Alexander D. Chalmers, Christina A. Bursill, Mary R. Myerscough.
Formal analysis: Mary R. Myerscough.
Funding acquisition: Mary R. Myerscough.
Investigation: Alexander D. Chalmers.
Methodology: Alexander D. Chalmers, Christina A. Bursill, Mary R. Myerscough.
Software: Alexander D. Chalmers.
Supervision: Mary R. Myerscough.
Visualization: Alexander D. Chalmers.
Writing – original draft: Mary R. Myerscough.
Writing – review & editing: Christina A. Bursill, Mary R. Myerscough.
References
1. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coro-
nary heart-disease; a prospective case-control study. Lancet, 1977; 1:965–968. https://doi.org/10.
1016/S0140-6736(77)92274-7 PMID: 67464
2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary
heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986; 256:2835–2838.
https://doi.org/10.1001/jama.1986.03380200073024 PMID: 3773200
3. Assmann G, Schulte H, von Eckardstein A, and Huang Y. High-density lipoprotein cholesterol as a pre-
dictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for
reverse cholesterol transport. Atherosclerosis, 1996; 124:S11–S20. https://doi.org/10.1016/0021-9150
(96)05852-2 PMID: 8831911
4. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving
intensive statin therapy. N Engl J Med. 2011; 365:2255–2267. https://doi.org/10.1056/
NEJMoa1107579 PMID: 22085343
5. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary
syndrome. N Engl J Med. 2012; 367:2089–2099. https://doi.org/10.1056/NEJMoa1206797 PMID:
23126252
6. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med. 2007; 357:2109–2122. https://doi.org/10.1056/NEJMoa0706628 PMID: 17984165
7. Haynes R, Jiang LX, Hopewell JC, Li J, Chen F, Parish S, Landray MJ, Collins R, Armitage J. HPS2-
THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ERniacin/laropiprant: trial
design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart
J. 2013; 34:1279–1291. https://doi.org/10.1093/eurheartj/eht055
8. Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, Cholez G, Keyserling C, Lalwani N,
Paolini JF, Dasseux J-L, Barbaras R, Baron R. CER-001, a HDL-mimetic, stimulates the reverse lipid
transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Ath-
erosclerosis 2014; 232:110–118. https://doi.org/10.1016/j.atherosclerosis.2013.10.018 PMID:
24401224
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 19 / 23
9. Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S. Lipoprotein
particle number, and incident cardiovascular events. An analysis from the JUPITER trial (Justification
for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) Circulation 2017;
135:2494–2504 https://doi.org/10.1161/CIRCULATIONAHA.116.025678 PMID: 28450350
10. Rohatgi A. High-density lipoprotein function measurement in human studies: Focus on cholesterol efflux
capacity. Prog. Cardiovas. Dis. 2015; 58:32–40. https://doi.org/10.1016/j.pcad.2015.05.004
11. Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA. High-density lipoprotein and atherosclerosis
regression: Evidence from preclinical and clinical studies. Circ Res. 2014; 114:205–213. https://doi.org/
10.1161/CIRCRESAHA.114.300760 PMID: 24385513
12. Kingwell B, Chapman M, Kontus A, Miller NE. HDL-targeted therapies: progress, failures and future.
Nat. Rev. Drug Discov. 2014; 13:445–464. https://doi.org/10.1038/nrd4279 PMID: 24854407
13. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein
plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990; 85:1234–1241. https://doi.org/10.1172/
JCI114558 PMID: 2318976
14. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis
induced by liver-directed gene transfer of apolipoprotein in A-I mice. Circulation, 1999; 100:1816–1822.
https://doi.org/10.1161/01.CIR.100.17.1816 PMID: 10534470
15. Belalcazar LM, Merched A, Carr B, Oka K, Chen K-H, Pastore L, Beaudet A, Chan L. Long-term stable
expression of human apoplipoprotein A-I mediated by helper-dependent adenovirus gene transfer
inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial
hypercholesterolemia. Circulation, 2003; 107:2726–2732. https://doi.org/10.1161/01.CIR.0000066913.
69844.B2 PMID: 12742997
16. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B. Regression and stabilization of
advanced murine atherosclerotic lisions: a comparison of LDL lowering and HDL raising gene transfer
strategies. Journal of Molecular Medicine, 2011; 89:555–567. https://doi.org/10.1007/s00109-011-
0722-x PMID: 21249329
17. Li R, Chao H, Ko KWS, Cormier S, Dieker C, Nour EA, Wang S, Chan L, Oka K, Gene therapy targeting
LDL cholesterol but not HDL cholesterol induces regression of advanced atherosclerosis in a mouse
model of familial hypercholesterolemia. J. Genet. Syndr. Ther. 2011; 2:106.
18. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA. Ele-
vating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced athero-
sclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation,
2001; 104:2447–2452. https://doi.org/10.1161/hc4501.098952 PMID: 11705823
19. Morton J, Bao S, Celermajer DS, Ng MK, Bursill CA. Striking differences between the atheroprotective
effects of high density lipoproteins in early-stage and late-stage atherosclerosis: Insights into the lack of
efficacy of HDL-raising therapy [abstract]. Heart, Lung and Circulation 2013; 22:S66–S67. https://doi.
org/10.1016/j.hlc.2013.05.158
20. Libby P. Inflammation in atherosclerosis. Nature, 2002; 420:868–874. https://doi.org/10.1038/
nature01323 PMID: 12490960
21. May RM. Thresholds and breakpoints in ecosystems with a multiplicity of stable states. Nature, 1977;
269:471–477. https://doi.org/10.1038/269471a0
22. Guckenheimer J, Labouriau IS. Bifurcation of the Hodgkin and Huxley equation—a new twist. Bulletin of
Mathematical Biology, 1993; 55:937–952.
23. Cohen A, Myerscough MR, Thompson RS. Athero-protective effects of high density lipoproteins (HDL):
An ODE model of the early stages of atherosclerosis. Bulletin of Mathematical Biology, 2014; 76:1117–
1142. https://doi.org/10.1007/s11538-014-9948-4 PMID: 24722888
24. Hao W, Friedman A. The LDL-HDL profile determines the risk of atherosclerosis: A mathematical model
PLOS One, 2014; 9:e90497. https://doi.org/10.1371/journal.pone.0090497 PMID: 24621857
25. Torii R, Oshima M, Kobayashi T, Takagi K, Tezduyar TE. Computer modeling of cardiovascular fluid-
structure interactions with the deforming-spatial-domain/stabilized space-time formulation. Computer
Methods in Applied Mechanics and Engineering, 2006; 195:1885–1895. https://doi.org/10.1016/j.cma.
2005.05.050
26. Olgac U, Poulikakos D, Saur SC, Alkadhi H, Kurtcuoglu V. Patient-specific three-dimensional simulation
of LDL accumulation in a human left coronary artery in its healthy and atherosclerotic states. American
Journal of Physiology—Heart and Circulatory Physiology 2009; 296:H1969–H1982. https://doi.org/10.
1152/ajpheart.01182.2008 PMID: 19329764
27. Peled M, Fisher EA. Dynamic aspects of macrophage polarization during atherosclerosis progression
and regression. Frontiers in Immunology, 2014; 5:579. https://doi.org/10.3389/fimmu.2014.00579
PMID: 25429291
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 20 / 23
28. Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunological
Reviews, 2014; 262: 153–166. https://doi.org/10.1111/imr.12218 PMID: 25319333
29. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayenr K, Moore K, Garabedian M,
Fisher EA. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of
plaque monocyte-derived cells. PNAS, 2011; 108:7166–7171. https://doi.org/10.1073/pnas.
1016086108 PMID: 21482781
30. Cobbold CA, Sherratt JA, Maxwell SRJ. Lipoprotein oxidation and its significance for atherosclerosis: a
mathematical approach. Bull. Math. Biol., 2002; 64:65–95. https://doi.org/10.1006/bulm.2001.0267
PMID: 11868338
31. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff
HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible
for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol Chem,
2002; 277:49982–49988. https://doi.org/10.1074/jbc.M209649200 PMID: 12376530
32. Jimi S, Sakata N, Matunagab A, Takebayashi S. Low density lipoproteins bind more to type I and III col-
lagens by negative charge-dependent mechanisms than to type IV and V collagens. Atherosclerosis,
1994; 107:109–116. https://doi.org/10.1016/0021-9150(94)90146-5 PMID: 7945553
33. Wang G-P, Deng Z-D, Ni J, Qu Z-L. Oxidized low density lipoprotein and very low density lipoprotein
enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macro-
phages. Atherosclerosis, 1997; 133:31–36. https://doi.org/10.1016/S0021-9150(97)00109-3 PMID:
9258404
34. Jovinge S, Ares MPS, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-α in response
to ox-LDL. Arteriosclerosis, Thrombosis, and Vascular Biology. 1996; 16:1573–1579. https://doi.org/10.
1161/01.ATV.16.12.1573 PMID: 8977464
35. Sanson M, Distel E, Fisher EA. HDL induces the expression of the M2 macrophage markers Arginase 1
and Fizz-1 in a STAT6-dependent process. PLOS One. 2013; 8:e74676. https://doi.org/10.1371/
journal.pone.0074676 PMID: 23991225
36. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory Prop-
erties of HDL. Circ Res. 2004; 95:764–772. https://doi.org/10.1161/01.RES.0000146094.59640.13
PMID: 15486323
37. Murao K, Ohyama T, Imachi H, Ishida T, Cao WM, Namihira H, Sato M, Wong NCW, Takahara J. TNF-
α stimulation of MCP-1 expression Is mediated by the Akt/PKB signal transduction pathway in vascular
endothelial cells. Biochem. Biophys. Res. Comm. 2000; 276:791–796. https://doi.org/10.1006/bbrc.
2000.3497 PMID: 11027549
38. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC,
Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in
cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis
and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039–2046. https://doi.org/10.1172/
JCI115532 PMID: 1752961
39. Doedel E, Champneys A, Fairgrieve A, Kuznetsov Y, Oldman B, Paffenroth R, Sandstede B, Wang X,
Zhang C. AUTO-07P: Continuation and bifurcation software for ordinary differential equations. http://
cmvl.cs.concordia.ca/. Accessed January 16, 2015.
40. Cilla M, Pena E, Martinez MA. Mathematical modelling of atheroma plaque formation and development
in coronary arteries. Journal of the Royal Society Interface. 2014: 11:20130866. https://doi.org/10.1098/
rsif.2013.0866
41. Tardif J-C, Ballantyne CM, Barter P, Dasseux J-L, Fayad ZA, Guertin M-C, Kastelein JJP, Keyserling C,
Klepp H, Koenig W, L’Allier PL, Lespe´rance J, Lu¨scher TF, Paolini JF, Tawakol A, Waters DD, for the
Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) investigators.
Effects of the high-density lipoproteinmimetic agent CER-001 on coronary atherosclerosis in patients
with acute coronary syndromes: a randomized trial. European Heart Journal 2014; 35:3277–3286.
https://doi.org/10.1093/eurheartj/ehu171 PMID: 24780501
42. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Shel-
don WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I
Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized control
trial. Journal of the American Medical Association. 2003; 290:2292–2300. https://doi.org/10.1001/jama.
290.17.2292 PMID: 14600188
43. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Mal-
tais JB, Weissman NJ, Fitzgerald PJ, Brewer B. A first-in-man, randomized, placebo-controlled study to
evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in
patients with acute coronary syndrome. Journal of the American College of Cardiology. 2010; 55:2727–
2735. https://doi.org/10.1016/j.jacc.2009.12.067 PMID: 20538165
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 21 / 23
44. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Wollard K, Lyon S, Sviridov
D, Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute changes in human athero-
sclerotic plaque. Circulation Research 2008; 103:1084–1091. https://doi.org/10.1161/CIRCRESAHA.
108.182063 PMID: 18832751
45. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR,
de Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. New
England Journal of Medicine 2014 Online, https://doi.org/10.1056/NEJMoa1409065 PMID: 25404125
46. Friedman A, Hao W. A mathematical model of atherosclerosis with reverse cholesterol transport and
associated risk factors. Bull Math Biol 2015; 77:758–781. https://doi.org/10.1007/s11538-014-0010-3
PMID: 25205457
47. Berrougui H, Khalil H. Age-associated decrease of high-density lipoprotein-mediated reverse choles-
terol transport activity. Rejuvenation Res 2009; 12;117–126. https://doi.org/10.1089/rej.2009.0840
PMID: 19405812
48. Andrews J, Janssan A, Nguyen T, Pisaniello AD Scherer DJ, Kastelein JJP, Merkely B, Nissen SE,
Kausik R, Schwartz GG, Worthley SG, Keyserling C, Dasseux J-L, Butters J, Girardi J, Miller R, Nicholls
SJ. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atheroscle-
rosis: rationale and design of the CARAT study. Cardiovascular Diagnosis and Therapy 2017; 7:45–51.
https://doi.org/10.21037/cdt.2017.01.01 PMID: 28164012
49. Zheng KH, van der Valk FM, Smits LP, Sandberg M, Dasseux J-L, Baron R, Barbaras R, Keyserling C,
Coolen BF, Nederveen AJ, Verberne HJ, Nell TE, Vugts DJ, Duivenvoorden R, Fayad ZA, Mulder
WJM, van Dongen GAMS, Stroes ESG. HDL mimetic CER-001 targets atherosclerotic plaques in
patients. Atherosclerosis 2016; 251:381–388. https://doi.org/10.1016/j.atherosclerosis.2016.05.038
PMID: 27263077
50. Easton R, Gille A, D’Andrea D, Davis R, Wright SD, Shear C. A multiple ascending dose study of
CSL112, an infused formulation of ApoA-I. Journal of Clinicial Pharmacology 2014; 54:301–310. https://
doi.org/10.1002/jcph.194
51. Zheng KH, Stroes ESG. HDL infusion for the management of atherosclerosis: current developments
and new directions. Current Opinion in Lipidology 2016; 27:592–596. https://doi.org/10.1097/MOL.
0000000000000349 PMID: 27653220
52. Kootte RS, Smits LP, van der Valk FM, Dasseux J-L, Keyserling CH, Barbaras R, Paolini JF, Santos
RD, van Dijk TH, Dallinga-van Thie GM, Nederveen AJ, Mulder WJM, Hovingh GK, Kastelein JJP,
Groen AK, Stroes ES. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT
and artery wall thickness in patients with FHA. Journal of Lipid Research 2015; 56:703–712. https://doi.
org/10.1194/jlr.M055665 PMID: 25561459
53. Kojima Y, Weissman IL, Leeper NJ. The role of efferocytosis in atherosclerosis. Circulation 2017;
135:476–489. https://doi.org/10.1161/CIRCULATIONAHA.116.025684 PMID: 28137963
54. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nature Reviews
Immunology, 2013; 13:709–721. https://doi.org/10.1038/nri3520 PMID: 23995626
55. Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis. Circulation Research,
2014: 114:1757–1771. https://doi.org/10.1161/CIRCRESAHA.114.301174 PMID: 24855200
56. Potteaux S, Gautier EL, Hutchinson SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG,
Randolph GJ. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic pla-
ques of ApoE-/- mice during disease regression. J. Clin. Invest. 2011; 121:2025–2036. https://doi.org/
10.1172/JCI43802 PMID: 21505265
57. Ougrinovskaia A, Thompson RS, Myerscough MR. An ODE model of early stages of atherosclerosis:
Mechanisms of the inflammatory response. Bulletin of Mathematical Biology, 2010; 72:1534–1561.
https://doi.org/10.1007/s11538-010-9509-4 PMID: 20440571
58. Chalmers AD, Cohen A, Bursill CA, Myerscough MR. Bifurcation and dynamics in a mathematical
model of early atherosclerosis. How acute inflammation drives lesion development. Journal of Mathe-
matical Biology, 2015; 71:1451–1480. https://doi.org/10.1007/s00285-015-0864-5 PMID: 25732771
59. Di Vito L, Porto I, Burzotta F, Trani C, Pirozzolo G, Niccoli G, Leone AM, Crea F. Radial artery intima-
media ratio predicts presence of coronary thin-cap fibroatheroma: A frequency domain-optical coher-
ence tomography study. International Journal of Cardiology, 2013: 168:191–1922. https://doi.org/10.
1016/j.ijcard.2012.12.082
60. Dabagh M, Jalali P, Tarbell JM. The transport of LDL across the deformable arterial wall: the effect of
endothelial cell turnover and intimal deformation under hypertension. American Journal of Physiology—
Heart and Circulatory Physiology. 2009: 297:H983–H996. https://doi.org/10.1152/ajpheart.00324.2009
PMID: 19592615
61. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY,
Feng L, Johnson RJ Uric acid stimulates monocyte chemoattractant protein-1 production in vascular
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 22 / 23
smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003:
41:1287–1293. https://doi.org/10.1161/01.HYP.0000072820.07472.3B PMID: 12743010
62. Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins M, Bhakta S,
McCarley D, Wiesent L, Wong B, Jarnagin K, Handel TM. Monomeric monocyte chemoattractant pro-
tein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. Journal of Biological Chemistry 1998:
273:33157–33165. https://doi.org/10.1074/jbc.273.50.33157 PMID: 9837883
Nonlinear dynamics and HDL efficacy in atherosclerotic plaque regression
PLOS ONE | https://doi.org/10.1371/journal.pone.0187674 November 21, 2017 23 / 23
